| Vol. 13.04 – 5 February, 2021 |
| |
|
|
| Researchers report on the dynamic behaviour of T follicular helper (TFH) cell clones during the germinal centre reaction. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors report a mechanism by which mutant p53 suppressed both cell-autonomous and non-cell-autonomous signaling to promote cancer cell survival and evasion of tumor immune surveillance. [Cancer Cell] |
|
|
|
| Scientists showed that elevation of CXCL1 or CXCL2 facilitated myeloid cell migration and simultaneously disrupted CD8+ T cell accumulation at tumor sites, causing accelerated tumor progression. [Science Advances] |
|
|
|
| Investigators developed a mouse model with a conditional allele to study the RNA exosome catalytic subunit DIS3. [Nature Genetics] |
|
|
|
| Researchers developed a chemical positive modulator of the purinergic P2RX7 receptor that potentiated αPD-1 treatment to effectively control the growth of lung tumors in transplantable and oncogene-induced mouse models and triggered long lasting antitumor immune responses. [Nature Communications] |
|
|
|
| Adoptive transfer of CD4+ T cells converted double negative T cells protected mice from diet-induced liver fat accumulation, lobular inflammation and focal necrosis. [Nature Communications] |
|
|
|
| Scientists showed that enapotamab vedotin, an antibody-drug conjugate targeting AXL, effectively targeted tumors that displayed insensitivity to immunotherapy or tumor-specific T cells in several melanoma and lung cancer models. [Cancer Research] |
|
|
|
| Investigators demonstrated the immunosuppressive potential of Nod1, the bacterial sensor of diaminopimelic acid-containing muramyl peptides. [Cell Reports] |
|
|
|
| The authors revealed a regulatory axis where T cell receptor signaling controls TCF1 expression through an E-protein-bound regulatory element in the Tcf7 locus, and this axis regulated both γδ T lineage commitment and effector fate. [Cell Reports] |
|
|
|
| Scientists compared the kinetics of immune cells in the tumour microenvironment upon treatment with immunotherapy combinations with different anti-tumour efficacies in the non-inflamed tumour model TC-1/A9. [British Journal of Cancer] |
|
|
|
| Immunogenicity of IMMUNEPOTENT CRP-induced cell death was evaluated in vitro, analyzing the principal biochemical characteristics of immunogenic cell death in MCF-7, MDA-MB-231 and 4T1 cells. [British Journal of Cancer] |
|
|
|
| The effect of profilin 1 (PFN1)-treated macrophages on colorectal cancer cell proliferation and migration was observed by subcutaneous tumorigenesis experiments in nude mice. [Cancer Gene Therapy] |
|
|
|
|
| The authors discuss the impact of haem oxygenase 1 induction in specific immune cell populations and provide new insights into the immunomodulation that accompanies haem catabolism, including its relationship to immunometabolism. [Nature Reviews Immunology] |
|
|
|
| Scientists suggest that T cell behavior might be influenced by resident T cell interactions with the bladder microbiota and other immunostimulants. [Trends in Immunology] |
|
|
|
|
| Immudex announced the launch of dCODE Dextramer® reagents. These DNA barcoded MHC Dextramer® reagents are designed to be compatible with the BD Rhapsody™ system to be used for multiplexing, allowing the identification of many different T-cell specificities in the same sample. [Immudex (Life Science Newswire, Inc.)] |
|
|
|
|
| March 1 – 2, 2021 Virtual |
|
|
|
|
|
| Karolinska Institutet – Stockholm, Sweden |
|
|
|
| Oslo University Hospital – Oslo, Norway |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| University of Luxembourg – Luxembourg City, Luxembourg |
|
|
|
| Cleveland Clinic – Cleveland, Ohio, United States |
|
|
|
|